Nowakowska Danuta, Saczko Jolanta, Szewczyk Anna, Michel Olga, Ziętek Marek, Weżgowiec Joanna, Więckiewicz Włodzimierz, Kulbacka Julita
Department of Prosthodontics, Wroclaw Medical University, Wroclaw 50-425, Poland.
Department of Molecular and Cellular Biology, Wroclaw Medical University, Wroclaw 50-556, Poland.
Exp Ther Med. 2020 Mar;19(3):2037-2044. doi: 10.3892/etm.2020.8462. Epub 2020 Jan 20.
The biological activity of chemical retraction/displacement agents in surrounding periodontal tissues is of unquestionable importance, but the activity of these agents has not been completely elucidated. In the present study, we aimed to evaluate the effects of vasoconstrictive retraction agents on primary human gingival fibroblasts (HGFs). A total of six commercial adrenergic solutions (0.05 and 0.01% HCl-epinephrine, two based on 0.05% HCl-tetrahydrozoline, 0.05% HCl-oxymetazoline, and 10% HCl-phenylephrine) and three experimental gel formulations (EG-1, EG-2, and EG-3) were used to treat primary HGFs. The biological effect of the retraction treatment on the expression of collagen types I and III was detected by performing immunocytochemical analysis. The generation of reactive oxygen species triggered by the retraction agents were evaluated by using the dichlorofluorescein (DCF) fluorescent probe. The effect of retraction agents on the expression of fibronectin was visualized by confocal laser scanning microscopy. According to the results, experimental retraction gels did not limit the expression of collagen types I and III. EG-3 even induced the synthesis of both types of collagen. The DCF assay indicated oxidative stress similar to the control cells for most of the selected retraction agents. Experimental gels did not cause degradation of the cellular shape and morphology of the primary HGFs. The proposed experimental retraction gels in the present study demonstrated higher biocompatibility with primary HGFs, suggesting their use as clinical vasoconstrictive agents for the application of gingival retraction with minimal damage to periodontal tissues.
化学性收缩/置换剂在周围牙周组织中的生物活性具有毋庸置疑的重要性,但这些药剂的活性尚未完全阐明。在本研究中,我们旨在评估血管收缩性收缩剂对原代人牙龈成纤维细胞(HGFs)的影响。总共使用六种市售肾上腺素能溶液(0.05%和0.01%盐酸肾上腺素、两种基于0.05%盐酸四氢唑啉、0.05%盐酸羟甲唑啉和10%盐酸去氧肾上腺素)和三种实验性凝胶制剂(EG-1、EG-2和EG-3)来处理原代HGFs。通过进行免疫细胞化学分析检测收缩处理对I型和III型胶原蛋白表达的生物学效应。使用二氯荧光素(DCF)荧光探针评估收缩剂引发的活性氧生成。通过共聚焦激光扫描显微镜观察收缩剂对纤连蛋白表达的影响。根据结果,实验性收缩凝胶并未限制I型和III型胶原蛋白的表达。EG-3甚至诱导了两种类型胶原蛋白的合成。DCF检测表明,对于大多数选定的收缩剂,氧化应激与对照细胞相似。实验性凝胶并未导致原代HGFs的细胞形状和形态退化。本研究中提出的实验性收缩凝胶对原代HGFs表现出更高的生物相容性,表明它们可作为临床血管收缩剂用于牙龈收缩,对牙周组织的损伤最小。